Holen Sie sich die Stockscreener-App
27.91
5.04%
-1.48
Handel nachbörslich:
27.94
0.03
+0.11%
Schlusskurs vom Vortag:
$29.39
Offen:
$28.57
24-Stunden-Volumen:
21.74M
Relative Volume:
0.58
Marktkapitalisierung:
$6.36B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
53.46
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
-6.22%
1M Leistung:
+44.01%
6M Leistung:
-40.77%
1J Leistung:
-2.00%
1-Tages-Spanne:
$27.65
$28.82
1-Wochen-Bereich:
$27.03
$31.44
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
27.91 | 6.70B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.41 | 51.68B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.65 | 49.57B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.47 | 42.18B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.62 | 36.40B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
569.11 | 24.85B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Dan Kenger Hims & Hers The Orange Pill Bottle Is Out And A Whole New Kind Of Healthcare Brand Is In - BuzzFeed
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today - The Globe and Mail
OMCL vs. HIMS: Which Stock Should Value Investors Buy Now? - Yahoo Finance Singapore
Hims & Hers nominates Kofi Amoo-Gottfried to its board of directors - marketscreener.com
Let’s Talk About Sex: The Identity of Intimacy - Hims & Hers Newsroom
Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means - MarketBeat
Hims & Hers Nominates DoorDash and Meta Veteran Kofi Amoo-Gottfried to Board of Directors - citybiz
Hims & Hers nominates ex-DoorDash CMO to board - Investing.com
Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors - Hims & Hers Newsroom
Hims & Hers (NYSE: HIMS) 2026 proxy details growth, control and pay - Stock Titan
-3.83% for Hims & Hers stock as broader selling pressure hits markets - Traders Union
A Look at Hims & Hers Health Inc (HIMS) After 3.8% Decline -- GF Value $36.82 vs Price $29.39 - GuruFocus
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
SpaceX Goes on $60 Billion AI Buying Spree - The Motley Fool
Bank of America resets Hims and Hers stock price target - thestreet.com
Should You Buy HIMS Stock Following Friday's Rally? - Yahoo Finance
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Hims & Hers builds scalable data-driven personalized care platform - MSN
Hims & Hers back in red as FDA doubles down on GLP-1 compounders - MSN
2026-04-26 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Hims & Hers Health, Inc. (HIMS) and Encourages Stockholders to Learn More About the Investigation | NYSE:HIMS | Press Release - Stockhouse
Hims & Hers expands personalized digital healthcare platform - MSN
Novo Nordisk sues Hims & Hers over compounded Wegovy, calls for permanent sales ban: HIMS stock tanks - MSN
Hims and Hers Expands Its Technology-Driven Consumer Health Platform - MSN
A Look At Hims & Hers Health (HIMS) Valuation After Fresh GLP-1 Analyst Endorsement And Pharma Partnerships - Yahoo Finance
Why Is Hims & Hers Health Stock Down 12% Today? - MSN
HIMS Stock Slides Premarket: Rival Telehealth Firm Ro Launches Aggressive Price Cuts In GLP-1 Subscription Fight - Stocktwits
Why Is Hims & Hers Health (HIMS) Stock Soaring Today - Yahoo Finance
HIMS Hims & Hers Health Inc: 5 Stock Signals After Novo Deal + Wednesday Predicted Opening Price? 📈 (g6weIcIV5G) - Fathom Journal
Hims & Hers Health Stock Short Interest Falls to 37.85% - Quiver Quantitative
Munich Reinsurance Co Stock Corp in Munich Takes Position in Hims & Hers Health, Inc. $HIMS - MarketBeat
HIMS plunges 51.2% in 6 months: Should you still hold the stock or sell? - MSN
Hims & Hers powers patient-provider connectivity via digital platforms - MSN
Hims & Hers Health discloses SEC investigation over copycat GLP-1s; stock falls - MSN
Hims & Hers Health Inc (HIMS) Stock Price, Trades & News - GuruFocus
Hims & Hers Health Inc (HIMS) Shares Surge 8.6% -- What GF Score of 81 Tells Investors - GuruFocus
Hims & Hers Stock Rallies After JPMorgan Bets On Its GLP-1 Pivot - TechStock²
HIMS Stock Rises as Options Activity Surges - GuruFocus
HIMS Stock Rises as J.P. Morgan Initiates Coverage with Overweig - GuruFocus
JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point? - Yahoo Finance
HIMS Initiates Coverage On JP Morgan -- Rating Set to Overweight - GuruFocus
How Expanding GLP‑1 Offerings and Partnering With LillyDirect At Hims & Hers Health (HIMS) Has Changed Its Investment Story - Yahoo Finance
Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims - Yahoo Finance
Hims rises as J.P. Morgan initiates at Overweight on rich catalyst path - Seeking Alpha
Hims & Hers (HIMS) Bets Big on Branded GLP-1s — J.P. Morgan Likes What It Sees - CoinCentral
HIMS Maintains Rating by B of A Securities -- Price Target Raised to $32 - GuruFocus
Hims & Hers Health (NYSE:HIMS) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Hims & Hers Health (NYSE:HIMS) Price Target Raised to $32.00 - MarketBeat
After A Rough Week, HIMS May Have Found Its Catalyst – JPMorgan Sees ‘Compelling Path - Stocktwits
JPMorgan initiates Hims & Hers stock at Overweight on GLP-1 outlook - Investing.com India
Investor relations - HIMS Investor Relations
HIMS stock pares losses after-hours: Citi flags 'big caveat' in Amazon's GLP-1 push that limits risk to Hims model - MSN
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):